TY  - JOUR
AU  - Quindos, Guillermo
AU  - Miranda-Cadena, Katherine
AU  - San-Millan, Rosario
AU  - Borroto-Esoda, Katyna
AU  - Canton, Emilia
AU  - Linares-Sicilia, Maria Jose
AU  - Hamprecht, Axel
AU  - Montesinos, Isabel
AU  - Tortorano, Anna Maria
AU  - Prigitano, Anna
AU  - Vidal-Garcia, Matxalen
AU  - Marcos-Arias, Cristina
AU  - Guridi, Andrea
AU  - Sanchez-Reus, Ferran
AU  - Machuca-Barcena, Jesus
AU  - Rodriguez-Iglesias, Manuel Antonio
AU  - Martin-Mazuelos, Estrella
AU  - Castro-Mendez, Carmen
AU  - Lopez-Soria, Leyre
AU  - Ruiz-Gaitan, Alba
AU  - Fernandez-Rivero, Marcelo
AU  - Lorenzo, Damaris
AU  - Capilla, Javier
AU  - Rezusta, Antonio
AU  - Peman, Javier
AU  - Guarro, Josep
AU  - Pereira, Joana
AU  - Pais, Celia
AU  - Romeo, Orazio
AU  - Ezpeleta, Guillermo
AU  - Jauregizar, Nerea
AU  - Angulo, David
AU  - Eraso, Elena
PY  - 2022
DO  - 10.3389/fcimb.2022.906563
UR  - http://hdl.handle.net/10668/20540
T2  - Frontiers in cellular and infection microbiology
AB  - Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators...
LA  - en
PB  - Frontiers Research Foundation
KW  - Candida
KW  - EUCAST
KW  - SCY-078
KW  - Antifungal resistance
KW  - Antifungal testing
KW  - Caspofungin
KW  - Ibrexafungerp
KW  - Micafungin
KW  - Antifungal agents
KW  - Candida
KW  - Candida albicans
KW  - Candida glabrata
KW  - Candida parapsilosis
KW  - Candida tropicalis
KW  - Candidiasis, invasive
KW  - Fluconazole
KW  - Glycosides
KW  - Micafungin
KW  - Triterpenes
TI  - In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study.
TY  - Research article
VL  - 12
ER  -